Trial Profile

A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2020 According to an Oxurion media release, Oxurion will follow a publication strategy for any further clinical data related to that presented in Aug 2019.
02 Sep 2019 According to an Oxurion media release, data from the study will be presented at the 19th European Society of Retina Specialists (EURETINA) 2019 Congress.
20 Aug 2019 According to an Oxurion media release, the company is now reviewing data from this trial .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com